Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 6/20 | 0.67 |
| ▸ | SKP1 | P63208 | 6/20 | 0.67 |
| ▸ | SKP2 | Q13309 | 6/20 | 0.67 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | PGK1 | P00558 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20046674 | 0.83 | CKS1B (0.70) | CKS1BSKP1SKP2DDB1CRBN | |
| SCHEMBL28933475 | 0.80 | CKS1B (1.00) | CKS1BSKP1SKP2ACHE | |
| SCHEMBL20046675 | 0.77 | DDB1 (0.56) | CKS1BSKP1SKP2DDB1CRBN | |
| SCHEMBL20046670 | 0.77 | CKS1B (0.64) | CKS1BSKP1SKP2DDB1CRBN | |
| SCHEMBL14614610 | 0.76 | CKS1B (0.59) | CKS1BSKP1SKP2DDB1CRBN | |
| SCHEMBL30365856 | 0.76 | CKS1B (0.60) | CKS1BSKP1SKP2DDB1CRBN | |
| SCHEMBL30899646 | 0.76 | CKS1B (0.60) | CKS1BSKP1SKP2DDB1CRBN | |
| SCHEMBL4063357 | 0.76 | CKS1B (0.69) | CKS1BSKP1SKP2MAP4K4GPR119 | |
| SCHEMBL14523364 | 0.75 | CKS1B (0.68) | CKS1BSKP1SKP2MAP4K4GPR119 | |
| SCHEMBL20046669 | 0.75 | CKS1B (0.58) | CKS1BSKP1SKP2DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | CKS1B 198/4885SKP1 4048/4885SKP2 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.